Clinical trials: Graves' Ophthalmopathy
Graves' Ophthalmopathy
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
The purpose of the study is to establish whether Bimatoprost eye drops are effective in reducing proptosis in inactive thyroid eye disease (TED) patients and improving quality of life in patients with TED.
- Trial name
- BIMA (NCT02059655)
- Testing
- Bimatoprost, Eye drop solution
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cardiff University
Hyperthyroidism, Graves Disease
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
Hyperthyroidism is the second most common endocrine disorder in the world with Graves' disease being the commonest. Anti thyroid drugs including methimazole, carbimazole, and propylthiouracil are effective treatments but take in…
- Trial name
- ChoPS (NCT03303053)
- Testing
- Cholestyramine Powder 4g, Prednisolone, Standard treatment
- Where
- 3 sites in Malaysia
- Volunteers
- 135 people
- Sponsor
- Clinical Research Centre, Malaysia
Graves' Ophthalmopathy
The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes.
- Trial name
- NCT00174057
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease, Graves' Orbitopathy
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R]) administered once every 3…
- Trial name
- OPTIC (NCT03298867)
- Testing
- Teprotumumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Amgen
Keratoconus, Corneal Ectasia
Corneal Tomographic Parameters in TGD
The current study involved analysis of the corneal tomographic parameters of patients with thyroid gland dysfunction (hyperthyroidism or hypothyroidism), including those with an autoimmune etiology, in comparison to healthy…
- Conditions
- Keratoconus, Corneal Ectasia, Thyroid Eye Disease
- Trial name
- NCT04433936
- Testing
- Pentacam tomography
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ameera Gamal Abdelhameed
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Graves Disease, Thyroid Cancer
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment.
- Trial name
- NCT07410637
- Testing
- Oral Glucose Tolerance Test
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Ulm
Graves' Ophthalmopathy
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
- Trial name
- NCT01969019
- Testing
- methylprednisolone, prednisone
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz
Pulmonary Fibrosis, Thyroid Eye Disease
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED.
- Trial name
- NCT05331300
- Testing
- LASN01
- Where
- 4 sites in Australia, Hong Kong
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Lassen Therapeutics 1 PTY LTD
Thyroid Neoplasms, Goiter, Nodular
Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy
We aim to study the effect of local anesthetic when used in conjunction with general anesthesia during thyroidectomy or parathyroidectomy.
- Conditions
- Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease
- Trial name
- NCT02205801
- Testing
- Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Graves Disease
HIFU vs RAI in the Relapsed Graves' Disease
Graves' disease (GD) is an autoimmune thyroid disorder caused by stimulating auto-antibodies to the thyrotrophin (TSH) receptor on thyroid follicular cells.
- Trial name
- NCT03013257
- Testing
- Echopulse
- Where
- Hong Kong
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Graves' Hyperthyroidism
Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism
The purpose of this study is to investigate if selenium supplementation to the standard treatment with anti-thyroid drugs in patients with Graves' hyperthyroidism, will lead to a fewer people with anti-thyroid treatment failure…
- Trial name
- GRASS (NCT01611896)
- Testing
- Selenium
- Where
- 8 sites in Denmark
- Volunteers
- 431 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial…
- Trial name
- HAZEL 401 (NCT07438405)
- Testing
- AMG 732
- Where
- 8 sites in United States, Poland and 2 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Colon Cancer, Lung Cancer
Predictive Genetic Risk Assessment Trial
This proof-of-principle clinical trial at Mayo Clinic studies how patients and their physicians understand and utilize predictive genetic risk assessment.
- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2
- Trial name
- PGT (NCT00782366)
- Testing
- SNP analysis
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Graves' Ophthalmopathy (GO)
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants.
- Trial name
- NCT03938545
- Testing
- RVT-1401 (Administered via subcutaneous injection)
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Disease
K1-70 - A Study in Subjects With Graves' Disease
This study is the first time that K1-70 will be administered to humans. The principal aim of this study is to obtain safety and tolerability data when K1-70 is administered as an IM injection or as an IV infusion to subjects with…
- Trial name
- NCT02904330
- Testing
- K1-70 intramuscular or K1-70 intravenous
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- AV7 Limited
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Thyroid Associated Ophthalmopathy, Hypercholesterolemia
Effects of Atorvastatin in Graves' Orbitopathy (GO)
Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD), being observed in ~25% of patients.
- Trial name
- STAGO (NCT03110848)
- Testing
- Atorvastatin, Methylprednisolone
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- University of Pisa